Last reviewed · How we verify

Azulfidine (Sulfasalazine)

Pfizer Inc. · FDA-approved approved Small molecule Quality 64/100

Anti-inflammatory and immunomodulatory properties, with 5-ASA as major therapeutic moiety in ulcerative colitis.

Sulfasalazine is a sulfonamide indicated for mild to moderate ulcerative colitis and remission maintenance. The drug exhibits anti-inflammatory effects primarily through its 5-ASA metabolite with bioavailability less than 15% for parent compound. Contraindications include obstruction, porphyria, and hypersensitivity to sulfonamides or salicylates. Clinical efficacy is established for ulcerative colitis management with prolonged remission benefits.

At a glance

Generic nameSulfasalazine
SponsorPfizer Inc.
Drug classSulfonamide; aminosalicylate
Target5-aminosalicylic acid (5-ASA) moiety; connective tissue affinity
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

Sulfasalazine's therapeutic action is mediated through its metabolites, primarily 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP). The drug exhibits anti-inflammatory and immunomodulatory properties demonstrated in animal and in vitro models. Clinical studies utilizing rectal administration of SSZ, SP, and 5-ASA have indicated that the major therapeutic action resides in the 5-ASA moiety. The drug demonstrates affinity for connective tissue and reaches relatively high concentrations in serous fluids, liver, and intestinal walls, as demonstrated in autoradiographic studies in animals.

Approved indications

Common side effects

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: